Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand

Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.

Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.

Indrajit Bandyopadhyay headshot

Glaxo (GSK) Miss Earnings Estimates in Q4, Revenues Beat

Glaxo miss earnings estimates in the fourth quarter of 2020 but beats the same for revenues. Stock down.

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?

Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.

Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen

Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.

Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants

Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.

Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine

Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.

Sheraz Mian headshot

Top Research Reports for Facebook, Novo Nordisk & SAP

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Novo Nordisk (NVO), and SAP SE (SAP).

Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer

The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.

J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings

J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal

Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.

Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.

Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline

The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline

Sheraz Mian headshot

Top Stock Reports for UnitedHealth, Netflix & Caterpillar

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group (UNH), Netflix (NFLX), and Caterpillar (CAT).

Sweta Killa headshot

5 Big ETF Stories of 2020 Worth Watching in 2021

We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.

Sweta Killa headshot

Wall Street Stories That Hit Headlines in 2020

With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.

Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

Sweta Killa headshot

Evergreen Tree of ETFs to Lighten Your Christmas

The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!

Sanghamitra Saha headshot

U.S. Dollar to Remain Weak in 2021? ETFs to Gain

U.S. dollar is expected to remain weak in 2021, after being beaten down this year.

The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK

The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK